Repositioning metformin for cancer prevention and treatment

Highlights • Metformin is associated with decreased cancer incidence. • AMPK-dependent and independent mechanisms of metformin action are described. • We discuss the clinical relevance of in vitro and animal studies with metformin. • We provide an overview of the current clinical trials with metform...

Full description

Saved in:
Bibliographic Details
Published in:Trends in endocrinology and metabolism 2013-09, Vol.24 (9), p.469-480
Main Authors: Quinn, Brendan J, Kitagawa, Hiroshi, Memmott, Regan M, Gills, Joell J, Dennis, Phillip A
Format: Article
Language:English
Subjects:
AMPK
Animals
cancer
chemoprevention
Clinical Trials as Topic
diabetes
Diabetes Mellitus, Type 2 - drug therapy
Disease Models, Animal
Endocrinology & Metabolism
Humans
Hypoglycemic Agents - pharmacology
metformin
Metformin - pharmacology
Neoplasms - drug therapy
Neoplasms - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Metformin is associated with decreased cancer incidence. • AMPK-dependent and independent mechanisms of metformin action are described. • We discuss the clinical relevance of in vitro and animal studies with metformin. • We provide an overview of the current clinical trials with metformin in cancer.
ISSN:1043-2760
1879-3061
DOI:10.1016/j.tem.2013.05.004